75N93020C00055

COVID-19. TO MANUFACTURE AND EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF GALIDESIVIR A BROAD SPECTRUM, ANTIVIRAL THERAPEUTIC.

National Institutes of Health · United States

This tender closed on Friday, September 30, 2022. Browse open opportunities

View Source

Time Left to Bid

Closed

ClosedHealthcare & MedicalFederal

Basic information

Reference number: 75N93020C00055
Issuing organization: National Institutes of Health · Find award history →
Government level: Federal
Solicitation type: Healthcare & Medical
Title: COVID-19. TO MANUFACTURE AND EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF GALIDESIVIR A BROAD SPECTRUM, ANTIVIRAL THERAPEUTIC.
Source: USASpending (Federal)
Source ID: usa-75N93020C00055

Details

Location: United States

Description

COVID-19. TO MANUFACTURE AND EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF GALIDESIVIR A BROAD SPECTRUM, ANTIVIRAL THERAPEUTIC. Awarded to: BIOCRYST PHARMACEUTICALS INC Agency: Department of Health and Human Services Sub-agency: National Institutes of Health Award type: DEFINITIVE CONTRACT

Dates

Publication: 2020/09/01 12:00:00 AM UTC
Closing date: 2022/09/30 12:00:00 AM UTC

Estimated value

$2.6M USD

Classification

Normalized category

Healthcare & Medical

Source: USASpending (Federal)

Last updated 2026-05-25, 2:30:15 p.m.

Data refreshed every 2 hours